



Alaska Medical Assistance DUR Committee Meeting
September 19, 2014

Agenda

- (1) Review of minutes from the last meeting
- (2) Review of agenda
- (3) Comments/Suggestions from Committee members
- (4) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - b. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. FDA Indication Changes
 1. Kalydeco
 - ii. FDA Label Changes
 1. Ampyra
 2. Linzess
 - iii. Periodic Review
 1. Actiq
 2. Adcirca
 3. Amrix
 4. Bactroban cream
 - c. Proposed New Prior Authorizations, Quantity Limits, Edits
 - i. Tobi Podhaler

<<Break>>

- (5) Past Intervention Informational Updates
 - a. Bisphosphonate – 3 month deployment review
 - b. Medication Assisted Opioid Therapy
- (6) FDA/DEA Updates
 - a. Incivek (telaprevir)
 - b. Hydrocodone combination products
- (7) FAERS Reports
- (8) Quality Measures
- (9) Standing Reviews
- (10) End of Meeting